Euronext today listed eureKING, the first French healthcare SPAC dedicated to biomanufacturing, on the regulated market of Euronext Paris. The SPAC traxes under the symbol KINGS. The offering raised €150 million ($156 million).
eureKING SPAC was founded by an international team of healthcare experts, including Michael Kloss, former Chairman and CEO of Panasonic Healthcare, Gérard Le Fur, former CEO of Sanofi, Alexandre Mouradian, Co-Founder and Administrator of eureKARE, Christophe Jean, Strategic Partner of the private equity fund Oraxys Environment, Hubert Olivier, President for France and Belgium of the pharmaceutical distribution and healthcare services group McKesson, and Rodolphe Besserve, CEO of eureKARE, through and on behalf of his affiliated entity, which is the first European network of “start-up studios” specialising in the creation, financing and support of innovative biotechnology companies.
eureKING’s goal is to create a European bio-CDMO (Contract Development Manufacturing Organisation) that will list on Euronext Paris and be a major player in the field of subcontracting the shaping and manufacturing of biopharmaceutical products, in order to support the development of new innovative therapies. Read more.
